AEON Biopharma, Inc. Stock-Based Compensation
AEON Biopharma, Inc. (AEON) reported Stock-Based Compensation of $3.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.66M, a 4.87% increase year-over-year.
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.93M, a 11.74% increase year-over-year.
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.59M, a 18.63% increase year-over-year.
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $414.00K, a 74.03% decline year-over-year.
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $5.32M, a 14.93% decline from fiscal 2024.
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.25M.
- AEON Biopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $5.89M.
| Period end | Share-based Payment Arrangement, Noncash Expense 2 month | Share-based Payment Arrangement, Noncash Expense 2 month as first filed | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 5 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 7 month | Share-based Payment Arrangement, Noncash Expense 7 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.59M 10-Q · filed 2026-08-12 | $5.18M derived: sum of 3 quarters · filed 2026-08-12 | $5.60M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | $1.93M 10-Q · filed 2026-05-14 | $3.52M derived: sum of 2 quarters · filed 2026-05-14 | $3.94M derived: sum of 3 quarters · filed 2026-05-14 | $5.52M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.01M derived: sum of 2 quarters · filed 2026-03-30 | $3.59M derived: sum of 3 quarters · filed 2026-08-12 | $5.32M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $414.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.00M derived: sum of 2 quarters · filed 2026-08-12 | $3.73M 10-Q · filed 2025-11-14 | $5.07M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.31M 10-Q · filed 2026-08-12 | $4.65M derived: sum of 3 quarters · filed 2026-08-12 | $6.25M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | $1.73M 10-Q · filed 2026-05-14 | $3.07M derived: sum of 2 quarters · filed 2026-05-14 | $4.67M derived: sum of 3 quarters · filed 2026-05-14 | $6.36M derived: sum of 4 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.94M derived: sum of 2 quarters · filed 2026-03-30 | $4.63M derived: sum of 3 quarters · filed 2026-03-30 | $6.25M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.29M derived: sum of 2 quarters · filed 2025-11-14 | $4.91M 10-Q · filed 2025-11-14 | ||||||
| 2024-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.31M 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | $1.62M 10-Q · filed 2025-05-14 | ||||||||
| 2023-12-31 | $3.77M 10-K · filed 2025-03-24 | ||||||||
| 2023-09-30 | $2.17M 10-Q · filed 2024-11-13 | $2.36M 10-Q · filed 2023-11-13 | |||||||
| 2023-07-21 | $3.23M 10-K · filed 2025-03-24 | $3.23M 10-Q · filed 2023-11-13 | |||||||
| 2023-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.50M 10-Q · filed 2024-08-12 | $4.17M derived: sum of 3 quarters · filed 2024-08-12 | ||||||
| 2023-03-31 | $1.36M 10-Q · filed 2024-05-14 | $3.03M derived: sum of 2 quarters · filed 2024-05-14 | |||||||
| 2022-12-31 | $1.67M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $5.89M 10-K/A · filed 2024-05-14 | |||||||
| 2022-09-30 | $4.22M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |